What is William Blair’s Estimate for Hologic Q2 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair raised their Q2 2025 earnings per share estimates for Hologic in a research report issued on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings of $1.07 per share for the quarter, up from their previous estimate of $1.05. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS.

HOLX has been the subject of several other research reports. Raymond James raised their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Trading Down 0.7 %

NASDAQ HOLX opened at $79.18 on Thursday. Hologic has a 12 month low of $67.59 and a 12 month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $18.39 billion, a PE ratio of 23.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98. The business’s 50-day moving average price is $80.84 and its two-hundred day moving average price is $78.22.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 EPS.

Institutional Investors Weigh In On Hologic

A number of hedge funds have recently modified their holdings of HOLX. Cetera Investment Advisers raised its stake in shares of Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 13,380 shares during the period. Clearbridge Investments LLC lifted its holdings in Hologic by 51.4% during the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock valued at $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Andra AP fonden boosted its position in Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after purchasing an additional 66,000 shares during the period. Swedbank AB increased its stake in shares of Hologic by 5.2% in the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after purchasing an additional 80,575 shares in the last quarter. Finally, National Bank of Canada FI raised its position in shares of Hologic by 352.0% in the first quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider’s stock valued at $22,474,000 after purchasing an additional 232,928 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.